Switch theme

🎉 M&A multiples are live!
Check it out!

PharmX Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for PharmX Technologies and similar public comparables like Doctor Care Anywhere, Echo IQ, and Benevolent AI.

All Healthcare Software Multiples Start Free Trial
PharmX Technologies logo PharmX Technologies logo

Sign up to access all valuation multiples

PharmX Technologies Overview

About PharmX Technologies

PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.

Founded

1950

HQ

Australia
Employees

109

Website

pharmx.com.au

Financials

LTM Revenue $4.3M

Last FY EBITDA $0.9M

EV

$28.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmX Technologies Financials

PharmX Technologies has a last 12-month revenue (LTM) of $4.3M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, PharmX Technologies achieved revenue of $4.2M and an EBITDA of $0.9M.

PharmX Technologies expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See PharmX Technologies valuation multiples based on analyst estimates

PharmX Technologies P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $4.3M XXX $4.2M XXX XXX XXX
Gross Profit $4.3M XXX $3.4M XXX XXX XXX
Gross Margin 100% XXX 81% XXX XXX XXX
EBITDA n/a XXX $0.9M XXX XXX XXX
EBITDA Margin n/a XXX 22% XXX XXX XXX
EBIT n/a XXX -$0.9M XXX XXX XXX
EBIT Margin n/a XXX -21% XXX XXX XXX
Net Profit $0.3M XXX -$1.1M XXX XXX XXX
Net Margin 7% XXX -27% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

PharmX Technologies Stock Performance

As of May 30, 2025, PharmX Technologies's stock price is AUD 0 (or $0).

PharmX Technologies has current market cap of AUD 47.9M (or $30.8M), and EV of AUD 43.6M (or $28.0M).

See PharmX Technologies trading valuation data

PharmX Technologies Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$28.0M $30.8M XXX XXX XXX XXX $0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PharmX Technologies Valuation Multiples

As of May 30, 2025, PharmX Technologies has market cap of $30.8M and EV of $28.0M.

PharmX Technologies's trades at 7.0x EV/Revenue multiple, and 49.1x EV/EBITDA.

Equity research analysts estimate PharmX Technologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

PharmX Technologies has a P/E ratio of 100.8x.

See valuation multiples for PharmX Technologies and 12K+ public comps

PharmX Technologies Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $30.8M XXX $30.8M XXX XXX XXX
EV (current) $28.0M XXX $28.0M XXX XXX XXX
EV/Revenue 6.6x XXX 7.0x XXX XXX XXX
EV/EBITDA n/a XXX 49.1x XXX XXX XXX
EV/EBIT n/a XXX -40.8x XXX XXX XXX
EV/Gross Profit 6.6x XXX n/a XXX XXX XXX
P/E 100.8x XXX -34.0x XXX XXX XXX
EV/FCF n/a XXX 9.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmX Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PharmX Technologies Margins & Growth Rates

PharmX Technologies's revenue per employee in the last FY averaged $38K, while opex per employee averaged $39K for the same period.

PharmX Technologies's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmX Technologies's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PharmX Technologies and other 12K+ public comps

PharmX Technologies Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $38K XXX XXX XXX
Opex per Employee XXX XXX $39K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 3% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX -2% XXX XXX XXX
Opex to Revenue XXX XXX 102% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms
Explore Valuation Multiples by Industry
Start Free Trial

PharmX Technologies Public Comps

See public comps and valuation multiples for Healthcare Software and EHR & Practice Management comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Benevolent AI XXX XXX XXX XXX XXX XXX
Alcidion Group XXX XXX XXX XXX XXX XXX
CurveBeam AI XXX XXX XXX XXX XXX XXX
Doctor Care Anywhere XXX XXX XXX XXX XXX XXX
Echo IQ XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

PharmX Technologies M&A and Investment Activity

PharmX Technologies acquired  XXX companies to date.

Last acquisition by PharmX Technologies was  XXXXXXXX, XXXXX XXXXX XXXXXX . PharmX Technologies acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by PharmX Technologies

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About PharmX Technologies

When was PharmX Technologies founded? PharmX Technologies was founded in 1950.
Where is PharmX Technologies headquartered? PharmX Technologies is headquartered in Australia.
How many employees does PharmX Technologies have? As of today, PharmX Technologies has 109 employees.
Is PharmX Technologies publicy listed? Yes, PharmX Technologies is a public company listed on ASX.
What is the stock symbol of PharmX Technologies? PharmX Technologies trades under PHX ticker.
When did PharmX Technologies go public? PharmX Technologies went public in 1973.
Who are competitors of PharmX Technologies? Similar companies to PharmX Technologies include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere.
What is the current market cap of PharmX Technologies? PharmX Technologies's current market cap is $30.8M
What is the current revenue of PharmX Technologies? PharmX Technologies's last 12 months revenue is $4.3M.
What is the current EV/Revenue multiple of PharmX Technologies? Current revenue multiple of PharmX Technologies is 6.6x.
Is PharmX Technologies profitable? Yes, PharmX Technologies is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.

Start Free Trial 🎦 Book a Call